Medtech Companies Are Still Treating Reimbursement as an Afterthought

Have you ever watched a strong Medtech team, real clinical signal, real unmet need, spend three years reverse-engineering a reimbursement strategy around something they'd already built?

I've seen it more than once.

The pilot never became a program.

Here's what happened every time: reimbursement was treated like a handoff. Build the device. Validate the clinical evidence. Get clearance. Then hand it to market access and ask them to figure out how the world will pay for it.

That sequence is why we have so many clinically excellent, commercially stranded devices.

If you can't name the CPT code or coverage pathway on day one of your product roadmap, you don't have a product strategy. You have a hope.

The questions aren't administrative. They're architectural.

Does an existing code cover this, or do you need a Category III CPT? Do you need a separate CMS National Coverage Determination, a parallel track that can take three to five years and requires its own clinical evidence standard? Can your target care site actually bill for the service your product enables?

An FQHC, a hospital outpatient department, and a private pulmonology practice are not interchangeable billing contexts. The same device, the same clinical workflow, three completely different reimbursement realities. That's not a scaling problem. It's an architecture problem.

So where do you start? Map your reimbursement pathway before you finalize your clinical trial design. Identify your target care site and understand its billing infrastructure. Then work backwards, let coverage reality shape your endpoints, your health economics methodology, and your partnership model. Retrofit work is always more expensive than designed-in work.

The Medtech Architect designs the revenue architecture the same way you design the device architecture.

A product that can't be reimbursed at scale, isn't a product. It's a very expensive proof of concept.